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Patterns of Drug-induced Mortality in Maine, 
2015 Update
by Marcella H. Sorg, Margaret Greenwald, and Jamie A. Wren
Drug addiction and drug-induced mortality have received a good deal of attention nationally and in Maine in recent 
years. The authors review overall trends in the patterns of drug overdoses that have continued for nearly two decades, 
including those involving opioid pharmaceuticals, and discuss the recent resurgence of the illicit drugs heroin and 
non-pharmaceutical fentanyl.  
Substance abuse and legitimate drug use in Maine exist along a complex series of continua. Use of 
illegal drugs by socially marginal people is only one 
extreme of a large, interrelated set of behavior patterns. 
Those who die from drug overdose come from all walks 
of life. They include people of all ages, although they 
disproportionately affect young and middle age adults. 
This marks the nineteenth year for which the 
authors and Maine’s Office of Chief Medical Examiner 
have tracked and reported on drug death statistics.1 In 
this article, we update two previous reports from 2003 
and 2010 (Sorg and Greenwald 2003; Sorg et al. 2010). 
We will review overall trends in drug overdose patterns 
that have continued for nearly two decades (see Figure 
1), including those involving opioid pharmaceuticals, 
and discuss the recent resurgence of illicit drugs heroin 
and non-pharmaceutical fentanyl. 
BRIEF HISTORY OF OPIOID ABUSE IN MAINE
During the 1990s, synthetic and long-acting narcotic pain medications were aggressively marketed and 
more heavily prescribed, with a resulting increase in 
patients who developed addictions. Originally marketed 
with the erroneous belief that patients taking synthetic 
opioids for pain would not become addicted, these 
drugs became much more accessible, initially through 
legitimate prescriptions. They subsequently became 
more generally available for diversion and misuse by a 
rapidly expanding number of people. 
A small minority of unethical prescribers took 
advantage of the opportunity to supply drugs to 
opioid-addicted persons, which exacerbated the problem. 
By the early 2000s, it became apparent in Maine and 
elsewhere that addiction to pharmaceutical pain medica-
tion was becoming a serious problem that had to be 
addressed by society and by medical professions. An 
expansion of medication-assisted treatment using meth-
adone helped many, but also complicated the picture. 
As these clinics expanded, so did opportunities for diver-
sion. At the same time, because methadone could also 
be used as an inexpensive drug for long-term pain relief, 
many providers began to prescribe it for pain. Oxocodone 
and methadone, both synthetic forms of opium, 
emerged as prominent addictive substances. The state 
began to experience the multiple consequences of the 
rising tide of substance-use disorders, including an 
increase in drug-induced deaths.
MAINE’S POLICY RESPONSES
Public policy interventions required attention by medical prescribers and the systems supporting 
them, as well as resources for an unprecedented number 
of citizens who had become addicted to opioids and who 
were at increased risk of overdose. Initially the number 
of treatment slots for drug addiction was expanded, 
including both traditional inpatient and outpatient 
treatment, as well as medication-assisted (methadone) 
outpatient treatment clinics. The Drug Enforcement 
Agency and the Maine Drug Enforcement Agency 
began to investigate and prosecute illegal prescribing 
practices. In 2004, Maine instituted one of the earliest 
prescription monitoring programs (PMP) in the nation, 
requiring dispensers to report “Schedule II” prescrip-
tions, including any opioid drug, tranquilizers, and 
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certain stimulants. Prescribers could now monitor the 
prescriptions of their patients to forestall “doctor shop-
ping.” In 2011, the Office of Chief Medical Examiner 
was given access to the PMP to investigate decedent 
prescriptions.
During the later 2000s, the opioid buprenorphine 
became available as an alternative medication-assisted 
treatment. Along with the help buprenorphine provided 
to many patients has come increased diversion of this 
drug also. This drug, however, contains naloxone, which 
limits its recreational use and reduces its mortality risks.
There have been multiple professional and policy 
efforts to limit or refine practices for prescribing opioid 
analgesics. The Maine Medical Association and the 
Maine Board of Licensure in Medicine have promoted 
use of the PMP, a single medical home for patients, 
patient contracts, and enhanced evaluation of pain to 
document need for prescriptions. Maine has developed 
similar rules for MaineCare (Medicaid), including limits 
on how much opioid medication a patient may receive 
and the length of time they receive such medication 
without additional approvals. Doctors in the state of 
Maine who prescribe opioids are required to take an 
online course on good practices for prescribing opioids 
in order to renew or obtain a medical license. Finally, 
prescribers as well as dispensers are now required to 
participate in the PMP, and the program has become 
much more efficient and timely. In addition, interstate 
compacts are being developed to share prescription data 
across state lines. 
First responders in Maine have struggled to address 
the exploding overdose rate, and law enforcement agen-
cies have likewise struggled to address the increase in 
heroin trafficking. For every fatal overdose, there are 
many nonfatal overdoses that require emergency services 
and medical treatment, increasing both public and 
private costs. Funding for the Maine Drug Enforcement 
Agency has been increased. New policy task forces have 
been formed at both the community and state levels, 
and funding for outpatient treatment has been increased. 
Naloxone, an emergency treatment to reverse opioid 
overdoses, has been made more widely available for first 
responders, including law enforcement officers. As this 
article is going to press, the Maine Legislature has just 
FIGURE 1: Number of Drug Deaths Occurring in Maine by Manner of Death, 1997–2015
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overturned a veto by the governor to pass a law allowing 
Naloxone to be sold over the counter.
OVERDOSE DEATH INVESTIGATION IN MAINE
All suspected overdose deaths are referred to Maine’s 
Office of Chief Medical Examiner (OCME). The 
OCME has statutory authority to investigate all suspi-
cious, accidental, and unintended deaths to certify their 
cause and manner. Prior to 2008, their investigation 
usually included a scene visit whenever practicable. An 
autopsy and full toxicology screen were routine in 
suspected drug deaths. With the dramatic statewide 
increase in these cases, the number of autopsies has been 
reduced, although full toxicology is still done on all 
suspected cases. The medical examiner has the legal 
authority to obtain hospital or other medical records 
upon request. The Maine OCME has two full-time 
forensic pathologists and two full-time 
death investigators headquartered in 
Augusta, as well as a small number of 
local medical examiner physicians who 
can investigate cases not brought in for 
autopsy. In the face of the large recent 
increase in overdose cases, personnel 
resources have not been adequate to 
send an OCME representative to the 
scenes when someone dies outside the 
hospital. They do send an investigator 
to do an external examination at the 
funeral home and take a toxicology 
sample. Law enforcement personnel, 
often the primary investigators at such 
scenes, use a standard protocol devel-
oped jointly by the OCME and Office 
of Attorney General to collect medical 
evidence and information from family 
or other witnesses.
Toxicology Testing
The investigation of potential 
drug deaths in Maine routinely 
includes full toxicology testing. Two 
types of tests are done: screening to 
detect the presence or absence of drugs; 
and confirmatory testing to measure 
the level of drugs that are present. The 
comprehensive toxicology screen is 
designed to detect a wide range of 
drugs, including analgesics, anticonvulsants, antihista-
mines, antidepressants, hypnotics, narcotics, sedatives, 
stimulants, and tranquilizers in very small amounts. 
(See sidebar for list of common drugs and their classes.)
The toxicology report includes a list of all drugs in 
the victim’s system at the time of death, but their pres-
ence does not necessarily mean they were a causal or 
contributing factor. For example, if a cardiac patient 
also on methadone maintenance had taken over-the-
counter drugs for a cold and then died of an accidental 
overdose of digoxin (a cardiac drug), the toxicology 
report would include methadone, digoxin, and perhaps 
drugs taken for a cold such as an antihistamine. However, 
only the digoxin toxicity would be listed as a cause of 
death on the death certificate. In some cases, use of a 
drug must be inferred from the presence of a metabo-
lized form identified by the toxicology test. Some drugs 
metabolize quickly, even after death. Breakdown of 
Common Name and Drug Class for Frequently Occurring Drugs
 
Drug
Common/ 
Brand Name
 
Drug Class
Amitriptyline Elavil Antidepressant
Alprazolam Xanax Anti-anxiety agent
Buprenorphine
Suboxone 
(Buprenorphine 
& Naloxone), 
Subutex
Narcotic
Diazepam Valium Anti-anxiety agent
Diphenhydramine Benadryl Antihistamine
Ethanol Alcohol Depressant
Fentanyl Duragesic Narcotic analgesic
Fluoxetine Prozac Antidepressant
Hydrocodone Vicodin Narcotic analgesic
Methadone Methadone Narcotic analgesic
Morphine
Morphine, MS 
Contin, Avinza
Narcotic analgesic
Nortriptyline Aventyl Antidepressant
Oxycodone
OxyContin, 
Roxicodone
Narcotic analgesic
Propoxyphene Darvon Narcotic analgesic
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chemicals may be more extensive if there is a delay in 
discovering the death. 
The relationship between drug levels provided in 
the toxicology report and the cause of death is not 
always straightforward. Toxic drug levels sometimes 
overlap with therapeutic levels. Further, there may be a 
large range of individual variation in tolerance for a 
given drug; doses needed in a person with high tolerance 
may be lethal for a person with low tolerance. This is 
especially common with opioids. Drugs may also 
interact with one another in dangerous ways. It is 
possible for an otherwise benign drug taken at thera-
peutic levels to be toxic in combination with other drugs.
The toxicology report is an essential component of 
any drug death investigation, but the interpretation 
requires knowledge, experience, care, and caution. For 
this reason, our analysis gives more weight to the 
medical examiner’s determination of cause of death than 
to the raw  data in the toxicology report.
Determining Manner of Death
The manner of death is clasified as natural, acci-
dental, suicide, or homicide. A small number of deaths 
classified as natural do involve drugs. These include 
deaths resulting from known effects of accepted medical 
treatment, such as digitalis toxicity from treatment of 
congestive heart failure. It is important to note that 
when death is due to a consequence of chronic (long-
term) substance abuse—such as withdrawal seizures 
from chronic alcoholism or cardiac inflammation (endo-
carditis) due to chronic intravenous drug use—the 
manner is also ruled natural (Hanzlick, Hunsacker, and 
Davis 2002). 
Deaths may be classified as suicide in Maine only if 
there is a “preponderance of evidence” that the victim 
intended to cause his own death. Such evidence might 
include a suicide note or history of previous attempts. 
Although drug abuse in and of itself carries with it an 
inherent risk of overdose and death, engaging in risky or 
reckless behavior is not generally considered sufficient 
evidence of suicidal intent. Medical examiners are 
bound by these legal guidelines. 
Maine’s strict guidelines for what can be judged 
suicide means that medical examiners classify as acci-
dents all drug deaths directly due to the unintended or 
unexpected, acute (sudden or short-term) toxic effects 
of a drug or poison.2 Accidental deaths thus constitute 
something of a composite category; deaths under this 
rubric may be the result of a range of heterogeneous 
drug uses. In a few cases, the medical examiner may not 
be able to determine if a case is suicidal or accidental 
and may classify the case as an undetermined manner 
of death.
The Certificate of Death
For each death investigated, a medical examiner is 
responsible for completion of a certificate of death, 
which includes information about the death event (time, 
place, how the injury or activity leading to death 
occurred), the manner of death (natural, accident, 
suicide, homicide, or undetermined), and the medical 
cause of death (up to four levels of causation may be 
specified, as well as significant conditions that contrib-
uted to the death). The death certificate information 
goes electronically from the OCME to the Maine 
Department of Health, Office of Data, Research and 
Vital Statistics. State-level mortality information is then 
forwarded to the Centers for Disease Control and 
Prevention’s National Center for Health Statistics, where 
the cause of death is coded. Both the state and the 
federal government use the standardized codes from 
death certificate data to generate statistics about popula-
tion mortality.
DEFINING “DRUG DEATHS”
In our studies, drug deaths, sometimes labeled “over-dose deaths” or “poisoning deaths,” include all medical 
examiner cases in which a drug was determined to be 
either a cause (primary cause or one of the three under-
lying causes) of death or a significant contributing factor. 
The deaths reported in this article are for the period 
from 2009 through 2015. These are occurrent deaths, 
that is, deaths that occurred within the state of Maine. 
Deaths of Maine residents who may have died in other 
states are not included here.
Deaths caused directly or indirectly by drugs may 
involve illicit substances (such as heroin or cocaine) or 
pharmaceutical drugs. Deaths caused by chronic 
alcohol abuse, in which no other drugs were implicated, 
were excluded; however, deaths in which both alcohol 
and drugs were causal or contributing factors have 
been included.
Drug deaths do not include deaths due to trauma, 
such as with a motor vehicle fatality, even if the dece-
dent had drugs in her system and may have been 
impaired. Although there is a legal impairment standard 
for alcohol impairment and a legal requirement for the 
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OCME to measure alcohol levels in the blood for motor 
vehicle fatalities, there is no legal standard for impair-
ment from drugs. 
Even when drugs are not the primary cause of 
death, they may be an important component of the 
overall causal sequence. For example, a medical exam-
iner may determine that lack of oxygen to the brain 
(brain anoxia) was the immediate cause of death, but 
that brain anoxia was due to heroin toxicity. In that case, 
heroin toxicity would be listed as an underlying 
(secondary) cause on the certificate of death.
MORTALITY RATES
The total annual number of drug-induced deaths occurring in Maine increased dramatically from 34 
in 1997 to 272 in 2015, with large increases in 2002 
and further increases during the last four years, 2012–
2015. As we show, the recent increase is due predomi-
nantly to accidental rather than suicidal overdoses and 
is largely the result of heroin and non-pharmaceutical 
fentanyl. Figure 1 shows the total number of suicidal 
and accidental deaths by year. Beginning in 2001, the 
number of drug-induced suicides has fluctuated, but 
has remained within 
the range of 25 to 38 
each year; that type 
of variation is likely 
random change due 
to the small number. 
During the same 
period, the number of 
accidental deaths rose 
sharply from 64 to 
124 between 2001 and 
2002, with another 
sharp increase from 
2012 to 2015, going 
from 115 to 272.
Since our last 
report in 2010 (Sorg 
et al. 2010), Maine 
has seen the number 
of deaths due to phar-
maceutical opioids 
stabilize, with a 
dramatic increase in 
illicit drug trafficking 
and abuse. As shown 
in Figure 2, in 2009 there were 18 deaths due to heroin, 
non-pharmaceutical fentanyl, and cocaine, a number 
that remained about level through 2011. But, begin-
ning in 2012, the number of deaths due to these illicit 
drugs began to increase sharply, doubling by 2012, 
doubling again by 2014, and again by 2015, an increase 
overall of 890 percent. In 2015, the number of illicit 
drug deaths surpassed the number caused by pharma-
ceutical opioids (Figure 2).
In the last few years the rate of drug-induced 
deaths, particularly those attributable to pharmaceu-
tical and illicit opioids, has risen drastically across the 
United States. According to a recent analysis by the 
Centers for Disease Control and Prevention, Maine was 
one of 14 states nationwide that saw a statistically 
significant percentage increase in drug-induced deaths 
from 2013 to 2014, with a 27.3 percent climb (Rudd 
et al., 2016). Among other New England states, both 
New Hampshire and Massachusetts also experienced 
statistically significant increases in drug-induced deaths 
during this same time period, with Massachusetts 
witnessing an increase of 18.8 percent, and New 
Hampshire, an increase of 73.5 percent. Among those 
14 states with statistically significant percentage 
FIGURE 2: Number of Deaths Due to Pharmaceutical Opioids or Illicit  
 Drugs, 2009–2015*
*Illicit drugs include heroin, non-pharmaceutical fentanyl, and cocaine. Drug categories are 
combined in some deaths.
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increases, Maine, New Hampshire, and 
Massachusetts ranked  third, second, and 
seventh, respectively. 
Maine’s drug deaths are spread 
throughout the state and thus are not a 
strictly urban phenomenon. In Table 1, we 
summarize the total number and 
percentage of drug deaths by county, 
compared to each county’s proportion of 
the 2010 Maine population. Although the 
proportion of drug deaths is similar to the 
population in most counties, Cumberland 
County has 4.4 percent more deaths than 
would be predicted based on its population, 
and Oxford County has 2.0 percent less. 
We calculated the rate per 100,000 for 
deaths occurring in each county (see Table 
2). Mortality rates in larger counties are 
similar to each other and also more stable 
over time, largely because they have larger 
populations (e.g., for 2013–2015, 
Androscoggin is 21.0; Cumberland is 20.8, 
and Kennebec is 21.6). In Table 2, we have 
used three-year rolling averages to smooth 
out some of the year-to-year random fluc-
tuations that occur in counties with small 
populations, but this small-number 
problem persists. Thus, some rate changes 
over time in the smaller counties are likely 
due to random fluctuations rather than 
changes in drug use. Nevertheless, several 
non-urban counties have experienced the 
lowest drug mortality rates per 100,000 population (e.g., 
for 2013–2015, Aroostook is 10.2, Franklin is 9.8, 
Oxford is 8.1, and Sagadahoc is 7.6). Most counties in 
Maine, however, have seen an increase over time in the 
rate of drug deaths. The map (Figure 3) shows the 
average ratio of drug deaths per 100,000 population in 
Maine’s counties in the 2009 to 2015 period.
DECEDENT CHARACTERISTICS
Some victims of drug-induced overdose in Maine are people most Mainers would characterize as 
marginal: without a stable place to live or a stable 
work history, perhaps with histories of mental illness or 
serious substance abuse problems. Others, however, are 
well-educated homeowners, employed at responsible 
jobs in a variety of skilled occupations. Aside from 
being (like most Mainers) overwhelmingly Caucasian, 
the population of those who die of drug-related causes 
is surprisingly diverse. 
Both men and women are included among over-
doses, but their distribution does not mirror the general 
population. Table 3 compares the age and sex structure 
of Maine drug deaths from 2009 to 2015 to that of the 
U.S. 2010 census for Maine. The drug death population 
is clustered in the age categories from 25 to 54. Males 
disproportionately occupy younger, and females older, 
age categories, whereas the Maine general population is 
more evenly distributed among age and sex categories. 
Men outnumber women approximately two to one 
among accidents (703 men vs 341 women), and women 
outnumber men by about 50 percent among suicides 
(130 women vs 90 men). During the 2009–2015 period, 
there were 1,320 deaths; decedent ages range from 17 to 
TablE 1: Total Number and Percentage of Drug Deaths by  
 County, 2009–2015* 
*Compared to county population (U.S. 2010 Census).
County
Number 
of Drug 
Deaths  
2009–2015
Percentage 
of Total 
Drug 
Deaths  
2009–2015
Percentage 
of 2010 
Maine 
Census 
Population
Percentage 
Deviation 
from 
Census
Androscoggin 129 9.8 8.1 1.7
Aroostook 47 3.6 5.4 -1.8
Cumberland 338 25.6 21.2 4.4
Franklin 22 1.7 2.3 -0.6
Hancock 44 3.3 4.1 -0.8
Kennebec 141 10.7 9.2 1.5
Knox 33 2.5 3.0 -0.5
Lincoln 31 2.3 2.6 -0.3
Oxford 31 2.3 4.3 -2.0
Penobscot 150 11.4 11.6 -0.2
Piscataquis 20 1.5 1.3 0.2
Sagadahoc 15 1.1 2.7 -1.6
Somerset 50 3.8 3.9 -0.1
Waldo 36 2.7 2.9 -0.2
Washington 38 2.9 2.5 0.4
York 195 14.8 14.8 0.0
Total 1,320 100 100 — 
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92, with the exception of two children age 2 and one age 
7. The average age of all decedents for the period from 
2009 to 2015 is 43. More than half (53 percent) of these 
decedents were aged 35 to 55. Accident victims are on 
average slightly younger (average age 41with sexes 
combined, males 40, females 43) than those who 
commit suicide (average age 51 with sexes combined, 
males 49, females 52), and twice as likely to be male. 
Compared to averages for Maine’s population as a 
whole, overdose victims are less educated and less likely 
to have been born in Maine. Table 4 compares the 2015 
drug deaths by manner of death to the Maine 2010 
census population. The 2015 accidental death victims 
are about twice as likely (16 percent) as the general 
population (9 percent) to have less than a high school 
education and approximately one-third as likely (8 
percent) as the general population (28 percent) to have 
a bachelor’s degree or higher. Accidental overdose 
victims are less likely (57 percent) than members of the 
general population (66 percent) to have been born in 
Maine;  suicidal overdose victims are 
even less likely (43 percent) to have 
been born in the state. Racial make-up 
is similar across categories.
As is true for many middle-aged 
Mainers, these drug death victims had 
chronic medical problems, including 
heart, lung, and liver diseases, as well as 
obesity. Conditions such as these can 
play a role in drug-related deaths by 
reducing physical capacity. For instance, 
liver diseases such as hepatitis or 
cirrhosis can reduce the ability of the 
liver to detoxify blood. This reduced 
ability helps keep blood drug levels 
dangerously high. Chronic obstructive 
pulmonary disease (COPD) reduces 
lung capacity, which can enhance the 
respiratory depression produced by 
high levels of opiates. Obesity can 
obstruct the airway, particularly in 
some body positions, thus potentially 
increasing the risk from respiratory 
depression caused by opiates. 
Cardiovascular disease further increases 
risks from respiratory depression by 
reducing the capacity of the heart and 
lungs to process oxygen. Witnesses to 
the circumstances of overdose deaths 
often describe the victim as “sleeping” and “snoring” 
heavily just before death, an unrecognized sign of respi-
ratory distress.
Decedents may have been taking medications 
prescribed legitimately for conditions such as pain, 
depression, or anxiety. These medications sometimes 
have dangerous side effects if taken incorrectly or 
combined with other drugs. They may interact danger-
ously with other drugs of abuse. Alcohol, as well as some 
medications prescribed for anxiety or depression, if 
taken in conjunction with opioids, can boost the blood 
levels—hence the toxic effects (Davis et al. 2012; Sorg et 
al. n.d.).
KEY DRUGS INVOLVED
Of the pharmaceutical drugs specifically listed on death certificates as either cause or contrib-
uting factor, three classes predominate: opioid anal-
gesics (including for example methadone, oxycodone 
TablE 2: Rate of Drug Deaths per 100,000 Population by  
 County, Three-year Rolling Averages, 2009–2015* 
*This occurrent ratio excludes deaths of Maine residents that occurred in other states.
County
2009–
2011
2010–
2012
2011–
2013
2012–
2014
2013–
2015
Androscoggin 13.6 13.6 13.3 18.0 21.0
Aroostook 9.3 9.3 11.6 9.7 10.2
Cumberland 13.4 13.8 14.7 16.4 20.8
Franklin 11.9 11.9 9.8 7.6 9.8
Hancock 12.9 8.0 6.1 8.6 11.6
Kennebec 13.6 14.5 15.3 15.8 21.6
Knox 10.1 10.9 10.9 12.6 15.1
Lincoln 9.7 9.7 12.6 13.5 16.4
Oxford 8.1 5.2 6.3 5.8 8.1
Penobscot 14.1 12.6 13.0 12.8 14.5
Piscataquis 24.7 20.9 5.7 5.7 13.3
Sagadahoc 3.8 5.7 6.6 8.5 7.6
Somerset 12.1 12.8 13.4 14.7 14.0
Waldo 13.8 14.6 15.5 13.8 12.0
Washington 14.2 18.3 19.3 19.3 18.3
York 12.7 11.0 10.5 13.9 16.6
Statewide 12.6 12.2 12.4 13.7 16.5
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and hydrocodone), antidepressants (most 
frequently SSRIs [selective serotonin reuptake 
inhibitors] such as fluoxetine or tricyclic 
antidepressants such as amitriptyline), and 
benzodiazepines (especially anti-anxiety 
agents such as diazepam and alprazolam). 
Alcohol (a depressant) and cocaine (a stimu-
lant) are also frequently listed. Heroin, which 
is a non-pharmaceutical opioid, has emerged as one of 
the most frequent causes, along with non-pharmaceu-
tical fentanyl (and acetyl-fentanyl). Heroin, cocaine, 
and non-pharmaceutical fentanyl are the most promi-
nent of the illicit drugs in Maine deaths.
Of all overdoses between 2009 and 2015, 67 
percent had at least one pharmaceutical drug mentioned 
as a cause of death (82 percent for accidents and 98 
percent for suicides). This is much greater than the 63 
percent for accidents and about the same as the 94 
percent for suicides noted in our 2003 article (Sorg and 
Greenwald 2003). However, it is important to note a 
change in how medical examiners certify deaths with 
multiple drugs; they are much more likely to mention 
all potential co-intoxicants on the death certificate. 
An overwhelming majority of pharmaceutical 
opioids and benzodiazepines implicated as causing or 
contributing to overdose deaths since 2009 lack any 
evidence of a prescription. For example, of the 96 cases 
in 2015 in which a pharmaceutical opioid was impli-
cated as a cause of death (35 percent of cases overall), 
only 7 percent had a prescription. 
Most drug-induced fatalities involve more than one 
drug. In our 2003 article, for about a quarter of the 
deaths that occurred in the 1997–2002 period, the toxi-
cology was so complex that the cause of death was listed 
simply as “polydrug” or “mixed drug.” Practice guide-
lines for medical examiners have changed since then, 
however (see Davis et al. 2012), and it is now more 
FIGURE 3: Average Rate of Drug Deaths per 100,000  
 Population by County, 2009–2015*
        *This occurrent ratio excludes deaths of Maine  
       residents that occurred in other states.
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TablE 3: Age and Sex Distribution for Drug Deaths from  
 2009  to 2015 Compared with Maine 2010 Census  
 Population
Age 
Categories
2010 Maine Population 2009–2015 Deaths
Male Female Both Sexes Male Female
Both 
Sexes
% %
<18 22 20 21 0 1 1
18-24 9 8 9 7 6 6
25-34 11 11 11 27 15 22
35-44 13 13 13 24 24 24
45-54 16 16 16 27 33 29
55-64 14 14 14 12 16 13
65+ 14 17 16 3 6 4
Total 100 100 100 100 100 100
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common to list any potentially inter-
acting or synergistic substances on 
the death certificate. 
Oxycodone and Methadone
Oxycodone is a synthetic opioid 
often prescribed for pain. Since 1995, 
it has been marketed in the long-
lasting form OxyContin, but is also 
prescribed in lower dose, short-
er-acting products. Once metabo-
lized, however, OxyContin and other 
commercial forms of oxycodone are 
indistinguishable. Oxycodone has 
been one of the key intoxicants found 
in Maine decedent toxicology since 
the late 1990s and is often the most 
commonly identified opioid across all 
overdose decedents in Maine. 
Methadone is a synthetic opioid 
with two distinct primary uses. 
Because it is long-acting, without the 
same euphoric high as heroin, it has 
long been used in the treatment of 
opioid addiction, prescribed in liquid, 
powder, or wafer form. Methadone is 
also frequently used in pill form for 
chronic pain. Toxicology screenings 
cannot discriminate between these 
various forms. Methadone pharma-
cology is particularly complex. 
Tolerances vary widely from one 
individual to another. The range of 
blood levels seen with therapeutic 
doses may overlap with the toxic 
range. As with other opioids, people 
can die of fairly low, theoretically safe, 
doses, often when alcohol or other 
drugs are present or if the individual 
has low tolerance. An individual’s 
tolerance can also change with 
circumstance. Tolerance is reduced 
for regular users who, for one reason or another, stop 
receiving regular doses, e.g., those who are in jail. When 
they resume taking dosages to which they had been 
accustomed, they are at greater risk for fatal overdose. 
The slow onset of methadone’s effects may prompt some 
users to take more methadone, with fatal effect. This can 
increase the risk of respiratory depression, the most 
common adverse effect of all opioids and the one most 
likely to prove fatal. 
Figure 4 illustrates the trends in the frequencies of 
deaths due to key opioids methadone and oxycodone, 
contrasted with heroin trends. The rates of oxycodone 
and methadone have been similar during the 2009–
2015 study period, temporarily dropping during 2012, 
FIGURE 4: Number of Deaths Caused by Methadone, Oxycodone,  
 and/or Heroin, Alone or in Combination with Other  
 Drugs, 2009–2015
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TablE 4: Demographic Characteristics of Decedents in  
 2015 by Manner of Death, Compared with Maine  
 2010 Census Population
2015 Deaths, 
Category
All Deaths Accidents Suicides
Maine 2010 
Population
%
Race
Caucasian 95 97 100 95
Education (ages 25+)
Less than high school 14 16 4 9
High School 85 84 96 91 
Bachelors or Higher 9 8 19 28
Nativity
Born in Maine 56 57 43 66
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but stablizing since 2013. These drugs are sometimes 
found together. 
Heroin and Non-pharmaceutical Fentanyl
Heroin is an illicit opioid associated with intrave-
nous drug use. Heroin is sometimes difficult to identify 
in toxicology. Because it metabolizes quickly in the body 
to morphine, the toxicology reports morphine, not 
heroin. Morphine could be pharmaceutical morphine 
sulfate, an opioid analgesic, or metabolized heroin. If 
they lack clear evidence of heroin from the scene inves-
tigation, medical examiners are likely to name the drug 
causing death as “morphine” on the death certificate, 
even though many of these cases are in fact due to 
heroin. To avoid undercounting heroin, our method has 
been to cast a wider net. We examine the scene investi-
gation data to rule out that the death is due to morphine 
sulfate pills and rule out that the decedent has a prescrip-
tion for pharmaceutical morphine; we then count any 
remaining cases of  morphine toxicity as heroin.
Fentanyl is likewise a substance found in toxi-
cology that may be pharmaceutical or, since 2011, 
non-pharmaceutical. This substance is being manufac-
tured in Asia and has been widely distributed as both 
powder and pills by drug traffickers in the United States. 
Maine began seeing non-pharmaceutical fentanyl 
deaths in 2012. Similar to our 
approach with heroin, we rule out the 
presence of known pharmaceutical 
fentanyl products such as fentanyl 
patches or known prescriptions for the 
decedent; we then count any remaining 
cases of fentanyl toxicity as non-phar-
maceutical fentanyl.  
Deaths caused by heroin had 
declined during the mid-2000s. They 
began to rise in 2011, along with 
non-pharmaceutical fentanyl. Fentanyl 
and its analogue acetyl-fentanyl are 
sometimes found alone, sometimes in 
combination with each other, and 
often combined with heroin in dece-
dent toxicology (see Figure 5). Illicit 
drug dealers often combine these drugs 
and sell the product as heroin. Fentanyl 
is many times more potent than heroin 
and often fatal.
Drug deaths caused by heroin or 
non-pharmaceutical fentanyl and its 
analogues were unevenly distributed around the state. 
The southernmost counties of Cumberland and York 
have had a disproportionate share of the heroin/
fentanyl deaths. Cumberland County has 21percent of 
Maine’s 2010 population, but has had 34 percent of the 
heroin/fentanyl deaths, 13 percent more than expected. 
York, with 15 percent of the population, had 19 percent 
of the heroin/fentanyl deaths. Many other counties 
have had fewer than expected heroin/fentanyl deaths 
through 2015, based on their poulations; for example, 
Penobscot, with 12 percent of Maine’s population, had 
9 percent of the heroin/fentanyl deaths, 3 percent less 
than would be expected. The map (Figure 6) displays 
the average rate of deaths per 100,000 due to heroin 
and non-pharmaceutical fentanyl by county over the 
2009–2015 period. The four most southern, contiguous 
counties along the Interstate-95 corridor, along with 
Washington County, have experienced the highest rates 
overall during this period.
Those who died due to pharmaceutical opioids are 
much older on average (males 43; females 46) than 
those who died due to heroin and/or non-pharmaceu-
tical fentanyl (males 38; females 36). But the distribu-
tion is skewed, as shown in Figure 7. For heroin and 
non-pharmaceutical fentanyl deaths, males far out- 
number females, and they cluster largely in the 25- to 
FIGURE 5: Number of Maine Drug Deaths in Which Heroin or  
 Fentanyl (and Its Analogues) Were Listed as the  
 Cause of Death, Alone or in Combination, 2009–2015
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34-age category (100 male decedents). The age distribu-
tion for females is similar to the pattern for pharmaceu-
tical opiods.
CONCLUSION
Substance abuse is a critical problem that continues to plague Maine state and local governments and 
the communities they serve. Death is only the most 
dramatic consequence of a behavior pattern associated 
with crime, increased accidents, lost time at work, 
serious health problems, and untold anguish for family 
and loved ones. 
A 2010 analysis of the impact of substance abuse on 
the state of Maine revealed that the total economic 
burdern resulting from drug and or alcohol abuse was 
over $1.4 billion in 2010 dollars, or $1,057 for every 
Maine resident (Rogers, Sorg, and Wren 2013). The 175 
drug-induced deaths in 2010 represent a $168.7 million 
in loss in potential lifetime earnings for those decedents. 
Among individuals in the labor force who had a drug 
problem in 2010, there was an approximatey $36.1 
million loss of productivity. Concerned members of the 
public often focus on the most exotic elements—illegal 
drugs such as heroin or cocaine or legal drugs such as 
methadone that seem to be used primarily by a definable 
population. Yet the problem is much more complex. 
FIGURE 6: Average Drug Deaths Due to Heroin and  
 Non-pharmaceutical Fentanyl per 100,000  
 Population by County, 2009–2015*
        *This occurrent ratio excludes  
       deaths of Maine residents that  
       occurred in other states.
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FIGURE 7: Age-Sex Distribution for Deaths Caused by Heroin  
 and Non-pharmaceutical Fentanyl, 2009–2015
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Study of Maine’s medical examiner files indicates 
that to reduce the risk of drug-related fatalities, policy 
initiatives must address this complexity of drug use. 
Here we make a few points on substance abuse issues 
coming from our study:
•	 At	 least	 one	 pharmaceutical	 drug	 is	 named	 as	
a cause of death (alone or in combination with 
other drugs) in the overwhelming majority (85 
percent) of drug deaths in Maine, 2009–2015. 
Most of these drugs have been diverted. A 
minority are prescribed, but misused.
•	 Within	the	past	three	years,	illicit	drugs	including	
heroin, non-pharmaceutical fentanyl formula-
tions, and cocaine are involved in over half 
(51 percent) of Maine drug deaths, frequently 
combined with pharmaceuticals or alcohol. This 
emergent pattern is worsening: the proportion 
of illicit drugs identified in drug death cases has 
increased from 27 percent in 2013 to 60 percent 
in 2015.
•	 Alcohol	 has	 been	 a	 prominent	 part	 of	 the	
substances listed on death certificates as either 
cause of death or contributing factor, named 
in 20 percent of cases in the 2009–2015 
period. Maine’s substance abuse problem is still 
frequently an alcohol abuse problem.
•	 Better	 public	 education	 on	 signs	 of	 respiratory	
distress might save lives. Unwitting witnesses 
to drug deaths frequently mistake respiratory 
distress for snoring and fail to summon medical 
assistance.
Our study of the forensic epidemiology of drug 
mortality continues. We hope our findings will provide 
a more nuanced understanding of the circumstances 
and risks of drug abuse and drug abusers and will 
prompt improved public policy initiatives that effec-
tively address the full range of Maine’s problems with 
drug use and abuse.  -
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ENDNOTES
1 The first report, funded by the U.S. Department of 
Justice Byrne Fund, covered the period 1997 to the end 
of June 2002. Funding from the U.S. Department of 
Justice allowed us to continue tracking through 2005. 
A second comprehensive report in 2010 was funded 
by the Offices of United States Attorneys. More recent 
tracking and funding for the current study have been 
supported by the Maine Office of Attorney General. 
2 This designation is consistent with guidelines recently 
published by the National Association of Medical 
Examiners (Hanzlick, Hunsacker, and Davis 2002) for 
determining the manner of death when drugs are 
involved. Jurisdictions outside Maine may use different 
criteria.
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